Converge Bios „Alles-Shop“ für Biotech-LLMs bringt 5,5 Millionen US-Dollar Startkapital ein

Developing new medications and biological products is complex, lengthy, and costly. On average, bringing a new drug to market takes about 10 years and requires an investment of [approximately $1 billion](https://medicalxpress.com/news/2024-07-drug-million.html). The process is extremely risky — [90%](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739/) of drug candidates fail during clinical trials.

Generative AI is becoming a powerful tool for drug discovery and development — there are currently [dozens of AI-discovered drugs](https://www.sciencedirect.com/science/article/pii/S135964462400134X) in clinical trials.

Biological languages, like DNA and RNA, aren’t just random sequences — they have intricate structures and rules, similar to the grammar and syntax of spoken languages. Just like how ChatGPT can instantly generate a string of words to answer a question, a model trained on biological data can help rapidly design optimized mRNA sequences for vaccines, potentially cutting months or even years from the process.

In the future, could this technology open up possibilities for creating personalized drugs tailored to an individual’s genome?